AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01592513 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BIS monitor
Description: BIS is a monitor of anesthetic depth approved by the FDA. It incorporates time-domain, frequency-domain and bi-spectral analysis of the EEG. This analysis is displayed as a dimensionless number between zero (deep anesthesia) and 100 (awake).~BIS values between 80-90 represent values corresponding to light/moderate sedation.~BIS is a valuable tool for assessing the depth of sedation and guiding the administration of sedative drugs.
Study NCT01119261 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Genotype-guided dosing algorithm
Description: Loading and monitoring dose according to genotype-guided dosing algorithm
Study NCT01022177 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: acupuncture
Description: acupuncture of the eye in traditional chinese schematics
Study NCT00886873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone
Study NCT00606996 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group interpersonal psychotherapy (IPT-G)
Study NCT00606996 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation on co-occurring disorders (PSYCHOED)
Study NCT00530088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: porfimer sodium
Description: IV
Study NCT00530088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Photdynamic Therapy (PDT)
Study NCT03684473 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Mindfulness-Based CBT & Trauma-Informed Yoga Intervention
Description: 8 Weekly Online modules consisting of one weekly video of yoga postures combined with breath awareness and daily guided meditation audios, and a breath technique manual form the foundation of the intervention. The trauma-informed component of the program uses specific language, movement cues, teacher qualities, and physical assists. The yoga intervention will emphasize full choice and control of the participant through invitational language such as, when you are ready, if you like before each body posture cue. Based on trauma-informed yoga best practices, a predictable foundation of yoga postures (with variations) will be followed in a consistent order each session to allow participants to anchor to the series.
Study NCT03039517 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACTitouch
Description: The device is applied to the lower leg (calf, ankle, and foot) and consists of an under-sock worn against the skin, a compression sleeve containing 4 inflatable chambers and a controller unit. The controller provides the airflow to inflate the chambers and monitors and adjusts the chamber pressure to maintain the intended treatment pressures.
Study NCT03039517 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Compression garments (stockings)
Description: Compression garments (stockings) now serve as the generally recommended standard of care for patients post DVT and will be utilized as the control compression method in this study. Compression garments utilized in this study will be below the knee style with a pressure range of 30-40 mmHg. If a patient does not have compression garments as indicated, these stockings will be provided.
Study NCT01119261 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-genotype-guided dosing algorithm
Description: Loading and monitoring dose according to non-genotype-guided dosing algorithm
Study NCT02522897 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Study NCT02522897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Study NCT02522897 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser
Study NCT01856140 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALLO-ASC(allogeneic adipose derived mesenchymal stem cell) injection
Study NCT01856140 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ALLO-ASC(allogeneic adipose derived mesenchymal stem cell) injection
Study NCT02800044 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wearing a non-invasive glucose sensor
Description: Glucose readings will be obtained from both a glucometer (fingerstick readings) and from the non-invasive glucose sensor at the following four timepoints: fasting, 1.5 to 2 hours after consuming a meal, and before and after 15-30 minutes of moderate exercise on a stationary bicycle.
Study NCT04498897 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vortioxetine
Description: * Baseline: Vortioxetine 10mg (or placebo) + Acamprosate~* First 2 weeks: Vortioxetine 5-10mg (or placebo) + Acamprosate~* Last 6 weeks: Vortioxetine 5-20mg (or placebo) + Acamprosate
Study NCT04498897 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Acamprosate
Description: * Baseline: Vortioxetine 10mg (or placebo) + Acamprosate~* First 2 weeks: Vortioxetine 5-10mg (or placebo) + Acamprosate~* Last 6 weeks: Vortioxetine 5-20mg (or placebo) + Acamprosate
Study NCT04498897 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acamprosate
Description: * Baseline: Vortioxetine 10mg (or placebo) + Acamprosate~* First 2 weeks: Vortioxetine 5-10mg (or placebo) + Acamprosate~* Last 6 weeks: Vortioxetine 5-20mg (or placebo) + Acamprosate
Study NCT03732092 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Coma Recovery Scale-Revised
Description: Patients with disorders of consciousness were assessed by Coma Recovery Scale-Revised (CRS-R). In addition, we selected three stimuli: 1) 1-octene-3-ol, 2) pyridine, 3) water. We presented these three stimuli in front of the patients nose for 3 seconds.
Study NCT03258476 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guanfacine Extended Release
Description: Intuniv (guanfacine) is a prescription medicine used to treat attention deficit hyperactivity disorder (ADHD) in children who are at least 6 years old. An open-label trail of guanfacine extended release (GXR 1-4 mg/daily; Intuniv™) suggested benefits in improving behavioral and emotional regulation in children and adolescents with symptoms of traumatic stress. However, to date no controlled clinical trial has been completed assessing the effects of GXR on traumatic stress symptoms in youths
Study NCT03258476 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Skills Therapy
Description: Mindfulness is a therapy for anxiety and stress. Mindfulness forms of therapy involve regulation of attention, maintaining it in immediate experience, regardless of the valence and desirability of the experience. To reduce anxiety, Mindfulness encourages observing and accepting anxiety-related thoughts
Study NCT03258476 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness Skills Therapy
Description: Mindfulness is a therapy for anxiety and stress. Mindfulness forms of therapy involve regulation of attention, maintaining it in immediate experience, regardless of the valence and desirability of the experience. To reduce anxiety, Mindfulness encourages observing and accepting anxiety-related thoughts
Study NCT03258476 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo oral capsule
Study NCT04795505 — intervention group
Intervention type: BEHAVIORAL
Intervention: Intervention
Description: The subsequent visit was through WeChat-based online consultations. Follow-up, assessments and feedback were done at each visit. After follow-up, medication adherence and risk factor modification status were assessed, then individualized feedback, encouragement and recommendations were provided.
Study NCT04795505 — intervention group
Intervention type: BEHAVIORAL
Intervention: Control
Description: The subsequent visit was through an offline outpatient clinic at 4 different community hospitals. Participants in this group received standard outpatient cardiology follow-up with formal cardiac rehabilitation and secondary prevention
Study NCT04135131 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: pilates mat exercises and home exercises
Description: Patients with low back pain were randomized into pilates (group 1) or home exercise group (group 2) 3 times/week for 8 weeks. Pilates mat exercise program comprised three sessions a week for 8 weeks (Monday, Wednesday, and Friday), with each session being scheduled for 1 h (5-min warm-up, 50-min exercise, and 5-min cooling) and each set comprising 10 repetitions. The home exercise program included the pelvic tilt in the supine position, hamstring stretch, hip flexors and lumbar extensor stretch, bridge, strengthening the abdominal muscles, cat/camel exercises in the crawl position, leaning on the forearms in the prone position, strengthening the back extensors, and crossed-arms/legs lift exercises.
Study NCT03380429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RELVAR/BREO
Description: RELVAR/BREO will be available at doses of 100/25 micrograms (µg) and 200/25 µg to be administered via ELLIPTA DPI. Subjects will be administered one inhalation of RELVAR/BREO once daily.
Study NCT05734235 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin E
Description: One Vitamin E tablet daily for 8 days.
Study NCT03380429 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RELVAR/BREO
Description: RELVAR/BREO will be available at doses of 100/25 micrograms (µg) and 200/25 µg to be administered via ELLIPTA DPI. Subjects will be administered one inhalation of RELVAR/BREO once daily.
Study NCT02007421 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Participants asked questions about recent experiences of anal intercourse in the last six months.
Description: Therefore, it is proposed we conduct a longitudinal study of the epidemiology of low risk and high risk HPV infection and related low grade and high grade anal cancers in HIV negative and HIV positive homosexual men who are 35 years or older. Participants are asked questions about recent experiences of anal intercourse in the last six months.~At baseline, all men (both HIV positive and HIV negative)will undergo a behavioural questionnaire, and anal swabs which will be tested for HPV and cytology. An HRA will also be performed on all men. Blood will be collected for HIV testing for HIV negative participants, syphilis and storage. Participants will be followed up for three years with one six-monthly visit in the first year then annually. A 6th study visit to discuss all study results will take place 2-3 months after the 5th study visit. A behavioural questionnaire, an anal swab, and HRA will be administered at all follow up interviews.
Study NCT02007421 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: High Resolution Anoscopy
Description: The HRA is performed on HIV positive and HIV negative participants by study doctor after an examination of the perianal region and perineum. The plastic anoscope is inserted into the anal canal and visualised under high resolution magnification. Biopsy samples will be taken by the clinician for histological assessment if there are any detected abnormalities.
Study NCT04006652 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ApoGraft
Description: ApoGraft is a cell based product, manufactured with mobilized peripheral blood.
Study NCT01726634 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Elastic Tapping
Study NCT02187120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: Tranexamic acid is a synthetic lysine derivative that inhibits fibrinolysis by blocking the lysine binding sites on plasminogen therefore inhibiting the conversion of plasminogen to plasmin. Intravenous injection of 1g Tranexamic Acid will be administered in the pre-hospital setting followed by 1g Tranexamic Acid infused intravenously over 8 hours initiated in the hospital emergency department.
Study NCT02187120 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04135131 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pilates mat exercises and home exercises
Description: Patients with low back pain were randomized into pilates (group 1) or home exercise group (group 2) 3 times/week for 8 weeks. Pilates mat exercise program comprised three sessions a week for 8 weeks (Monday, Wednesday, and Friday), with each session being scheduled for 1 h (5-min warm-up, 50-min exercise, and 5-min cooling) and each set comprising 10 repetitions. The home exercise program included the pelvic tilt in the supine position, hamstring stretch, hip flexors and lumbar extensor stretch, bridge, strengthening the abdominal muscles, cat/camel exercises in the crawl position, leaning on the forearms in the prone position, strengthening the back extensors, and crossed-arms/legs lift exercises.
Study NCT02412267 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: O-ICE (ofatumumab, Ifosfamide, Carboplatin, Etoposide)
Description: Ofatumab in combination with ICE (Ifosfamide, Carboplatin, Etoposide) are given to subjects according to protocol schedule
Study NCT03195413 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided forearm nerve block
Description: An ultrasound machine will be used to identify the median, radial, and ulnar nerves in the forearm, so that a needle may be used to apply lidocaine into the soft tissue space around those nerves.
Study NCT03195413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1:1 volume measured solution of: 1% lidocaine without epinephrine and 0.5% bupivacaine without epinephrine
Description: This is the anesthetic solution that will be administered during the ultrasound-guided nerve block
Study NCT03195413 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bedside ultrasound machine
Description: This is the device that will be used to visualize tissues during the ultrasound-guided nerve block.
Study NCT01747681 — intervention group
Intervention type: PROCEDURE
Intervention: Microfracture
Study NCT02139644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FS MDPI
Description: FS MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate (Fp) and salmeterol xinafoate (Sx) dispersed in a lactose monohydrate excipient and contained within a reservoir. A metered dose of drug is delivered to a dose cup via an air pulse activated when the cap is opened.~During the treatment period, participants were randomized to either 100/12.5 mcg Fp/Sx or 50/12.5 mcg Fp/Sx in the morning and evening for a total daily dose of 200/25 mcg or 100/25 mcg Fp/Sx.~Participants were instructed to rinse their mouth and expectorate (not swallow) after study drug administration.
Study NCT02139644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fp MDPI
Description: Fp MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate dispersed in a lactose monohydrate excipient and contained within a reservoir. A metered dose of drug is delivered to a dose cup via an air pulse activated when the cap is opened.~During the treatment period, participants were randomized to either 100 mcg or 50 mcg of Fp one inhalation twice a day for a total daily dose of 200 mcg or 100 mcg.~Participants were instructed to rinse their mouth and expectorate (not swallow) after study drug administration.
Study NCT02139644 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo MDPI
Description: Placebo administered via a multidose dry powder inhaler (MDPI) one puff in the morning and one puff in the evening for 12 weeks.
Study NCT02139644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: albuterol/salbutamol
Description: A short-acting β2-adrenergic agonists (SABA), albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI), was provided to be used as needed for the relief of asthma symptoms during both the run-in and treatment periods (to replace the subject's current rescue medication).
Study NCT03380429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol
Description: Salbutamol will be available at a dose of 100 µg to be administered via MDI. Subjects will be administered salbutamol as and when required.
Study NCT02139644 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: albuterol/salbutamol
Description: A short-acting β2-adrenergic agonists (SABA), albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI), was provided to be used as needed for the relief of asthma symptoms during both the run-in and treatment periods (to replace the subject's current rescue medication).
Study NCT02139644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate
Description: QVAR (beclomethasone dipropionate) 40 mcg inhalation aerosol is a pressurized MDI that contains a Food and Drug Administration (FDA)-approved formulation of beclomethasone dipropionate. Patients took 1 puff twice a day from open-label QVAR 40 mcg hydrofluoroalkane (specifically, HFA-134a) metered-dose inhaler (MDI) for the duration of the Run-in Period (14-21 days) and prior to randomization. A clinically equivalent dose of inhaled corticosteroid (ICS) was substituted in countries where QVAR 40 mcg was not available.
Study NCT02139644 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Beclomethasone dipropionate
Description: QVAR (beclomethasone dipropionate) 40 mcg inhalation aerosol is a pressurized MDI that contains a Food and Drug Administration (FDA)-approved formulation of beclomethasone dipropionate. Patients took 1 puff twice a day from open-label QVAR 40 mcg hydrofluoroalkane (specifically, HFA-134a) metered-dose inhaler (MDI) for the duration of the Run-in Period (14-21 days) and prior to randomization. A clinically equivalent dose of inhaled corticosteroid (ICS) was substituted in countries where QVAR 40 mcg was not available.
Study NCT01681082 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Chi training
Description: 24 form Yang style Tai Chi. 50 minute sessions, twice weekly.
Study NCT02346565 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Exercise ECG
Study NCT02346565 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Stress Echocardiography
Study NCT02039531 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Plasma rich in growth factors
Study NCT02039531 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic Acid
Study NCT04011475 — intervention group
Intervention type: DRUG
Intervention: Tiotropium + Olodaterol
Description: Spiolto®
Study NCT04011475 — intervention group
Intervention type: DRUG
Intervention: Other LABA/LAMA
Description: tiotropium/olodaterol, indacaterol/glycopyrronium, vilanterol/umeclidinium
Study NCT04011475 — intervention group
Intervention type: DRUG
Intervention: LAMA
Description: aclidinium bromide, glycopyrronium, tiotropium, umeclidinium
Study NCT03380429 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salbutamol
Description: Salbutamol will be available at a dose of 100 µg to be administered via MDI. Subjects will be administered salbutamol as and when required.
Study NCT03380429 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smart phone app
Description: Subjects will be required to download an app associated with sensor on their smartphone. The sensors attached to the inhalers will be connected to the smartphone via Bluetooth.
Study NCT03380429 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HCP Dashboard
Description: The information from sensors will be reviewed by the HCP via an online dashboard.
Study NCT03380429 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sensors
Description: Clip-on sensors will be fitted to electronically record the actuation data.
Study NCT02595567 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Indwelling tunneled pleural catheter (ITPC)
Description: ITPCs have been shown to successfully and safely control dyspnea in patients with malignant pleural effusions. Compared to the large amount of published data regarding the use of indwelling tunneled pleural catheters in malignant effusions, there is a paucity of data regarding the use of ITPC in liver disease for the treatment of hepatic hydrothorax.
Study NCT02184468 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Simultaneously dispatch of firefighters and/or police in case of OHCA
Description: In case of OHCA, firefighters and/or police trained in CPR and equipped with AEDs will be dispatched in parallel with EMS in nine counties in Sweden.
Study NCT06367582 — intervention group
Intervention type: DEVICE
Intervention: Vertebroplasty (VP)
Description: Vertebroplasty is a procedure in which a special medical-grade cement mixture is injected into a fractured vertebra to relieve pain
Study NCT06367582 — intervention group
Intervention type: DEVICE
Intervention: Kyphoplasty (KP)
Description: Kyphoplasty is a procedure in which a special medical-grade cement mixture is injected into a fractured vertebra to relieve pain
Study NCT06367582 — intervention group
Intervention type: DEVICE
Intervention: Pedicular Screw Augmentation (PSA)
Description: Pedicular Screw Augmentation is a procedure in which a special medical-grade cement mixture is injected into pedicular screws in order to augment fixation strength
Study NCT02098343 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APR-246
Description: Intravenous infusion.
Study NCT03490331 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transplantation surgery of genetically corrected cultured epidermal autograft (ATMP)
Description: Surgergical procedure for transplantation under anaesthesia of genetically corrected cultured epidermal autograft (Hologene17) on blistering skin areas of JEB patients. By taking some autologous epidermal cells, a new layer of transgenic tissue is grown in the laboratory. This layer of tissue - containing genetically modified stem cells - is then implanted by a surgeon into the damaged area. The implantation can be done in one or more areas and repeated in case of failure of the first surgery.
Study NCT02875431 — intervention group
Intervention type: PROCEDURE
Intervention: Patients undergo ACDF or cervical vertebral body replacement
Study NCT03327532 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Clinical examination centered on congestion
Description: Clinical examination centered on congestion will be performed within 72 hours of admission and before discharge from hospital